Table 1

Efficacy of pegylated interferon and ribavirin in the treatment of G4 HCV infection

TrialTreatment historyNumber of patients treated—suffering from G4 HCVPatient characteristicsTreatmentSVR rate
Marcellin et al16Naïve31751 bridging fibrosis/cirrhosis
214 no bridging fibrosis/cirrhosis
PEG-IFN α2a or PEG-IFN α2b+RBV (clinician discretion)27.5%
41%
El Raziky et al17Naïve37186.3% cirrhotic
5.9% cirrhotic
PEG-IFN α2a+RBV (n=1985)
PEG-IFN α2b+RBV (n=1733)
59.6%
53.9%
Kamal et al19Naïve358Highly selected, few cirrhoticVirus negative week 4–24 weeks PEG-IFN α2b
Virus negative week 12–36 weeks PEG-IFN α2b
Virus positive week 4+12–48 weeks PEG-IFN α2b
86%
76%
56%
Poynard et al22Experienced68Fibrosis stage 2, 3 and 4PEG-IFN α2b+RBV28%
  • PEG-IFN pegylated interferon; RBV ribavirin; SVR sustained virologic response.